Clinical Trial Update: FGF19 Overexpression Combination Unified Study in HCC-19 [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating a FGF19 overexpression combination for hepatocellular carcinoma, currently recruiting. Sponsor: RenJi Hospital.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Snippet

Sponsor: RenJi Hospital | Conditions: HCC - Hepatocellular Carcinoma | Phase 2 | Status: RECRUITING